Metformin: A promising drug for human cancers (Review)
- Authors:
- Hongnian Wu
- Dan Huang
- Hong Zhou
- Xueqin Sima
- Zhe Wu
- Yanling Sun
- Long Wang
- Ying Ruan
- Qian Wu
- Feng Wu
- Tonghui She
- Ying Chu
- Qizhi Huang
- Zhifeng Ning
- Hao Zhang
-
Affiliations: Department of Human Anatomy, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Burn and Plastic Surgery, Enshi State Central Hospital, Enshi, Hubei 445099, P.R. China, Department of Histology and Embryology, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Microbiology, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Dermatology, Clinical Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Nursing School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Stomatology and Optometry School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Pathology, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Clinical Lab, Second Affiliated Hospital, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Human Anatomy, Basic Medicine School, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Institute of Precision Cancer Medicine and Pathology, Department of Pathology, Jinan University Medical College, Guangzhou, Guangdong 510630, P.R. China - Published online on: May 12, 2022 https://doi.org/10.3892/ol.2022.13325
- Article Number: 204
-
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Nasri H and Rafieian-Kopaei M: Metformin: Current knowledge. J Res Med Sci. 19:658–664. 2014. | |
|
Top WMC, Kooy A and Stehouwer CDA: Metformin: A narrative review of its potential benefits for cardiovascular disease, cancer and dementia. Pharmaceuticals (Basel). 15:3122022. View Article : Google Scholar : PubMed/NCBI | |
|
Kramer JR, Natarajan Y, Dai J, Yu X, Li L, El-Serag HB and Kanwal F: Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 15:322442021. View Article : Google Scholar | |
|
Gralewska P, Gajek A, Marczak A and Rogalska A: Metformin affects olaparib sensitivity through induction of apoptosis in epithelial ovarian cancer cell lines. Int J Mol Sci. 22:105572021. View Article : Google Scholar | |
|
Tsogas FK, Majerczyk D and Hart PC: Possible role of metformin as an immune modulator in the tumor microenvironment of ovarian cancer. Int J Mol Sci. 22:8672021. View Article : Google Scholar | |
|
Adeyemi SA and Choonara YE: Current advances in cell therapeutics: A biomacromolecules application perspective. Expert Opin Drug Deliv. 12:1–18. 2022. View Article : Google Scholar | |
|
Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B and Liu B: Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: A revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 15:442022. View Article : Google Scholar | |
|
Marciano O, Mehazri L, Shpungin S, Varvak A, Zacksenhaus E and Nir U: Fer and fert govern mitochondrial susceptibility to metformin and hypoxic stress in colon and lung carcinoma cells. Cells. 10:972021. View Article : Google Scholar | |
|
Mohammadi S, Arefnezhad R, Danaii S and Yousefi M: New insights into the core Hippo signaling and biological macromolecules interactions in the biology of solid tumors. Biofactors. 46:514–530. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YS, Hwang KA, Go RE, Kim CW and Choi KC: Gene therapy strategies using engineered stem cells for treating gynecologic and breast cancer patients (Review). Oncol Rep. 33:2107–2112. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, Okada T, Hisamoto A and Tanimoto M: Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer. 46:255–261. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lankheet NA, Schaake EE, Burgers SA, van Pel R, Beijnen JH, Huitema ADR and Klomp H; NEL Study Group, : Concentrations of erlotinib in tumor tissue and plasma in non-small-cell lung cancer patients after neoadjuvant therapy. Clin Lung Cancer. 16:320–324. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M and Kroemer G: Immunological off-target effects of imatinib. Nat Rev Clin Oncol. 13:431–446. 2016. View Article : Google Scholar | |
|
Joensuu H: Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin (Munich). 15 (Suppl 1):S28–S30. 2002. | |
|
Cohen C, Pop D, Icard P, Berthet JP, Venissac N and Mouroux J: Is there a place for thoracoscopic enucleation of esophageal gastrointestinal stromal tumors? Thorac Cardiovasc Surg. 67:585–588. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YH, Yang SF, Yang CK, Tsai HD, Chen TH, Chou MC and Hsiao YH: Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells. Mol Med Rep. 23:882021. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng L, Lv W, Zhou Y, Lin X and Yao J: Progress on the mechanism for aspirin's anti-tumor effects. Curr Drug Targets. 22:105–111. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira PMR, Mandleywala K, Ragupathi A and Lewis JS: Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors. Clin Cancer Res. 26:6215–6229. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira A, de Souza Lima ML, da Silva-Junior AA, Silva EDS, de Araújo Júnior RF, Martins AA, Alves JSF, de Santana Oliveira A, Ferreira LDS, de Araújo Costa ECT, et al: In vitro-in vivo availability of metformin hydrochloride-PLGA nanoparticles in diabetic rats in a periodontal disease experimental model. Pharm Biol. 59:1576–1584. 2021. View Article : Google Scholar | |
|
Horas K, van Herck U, Maier GS, Maus U, Harrasser N, Jakob F, Weissenberger M, Arnholdt J, Holzapfel BM and Rudert M: Does vitamin D deficiency predict tumour malignancy in patients with bone tumours? Data from a multi-center cohort analysis. J Bone Oncol. 25:1003292020. View Article : Google Scholar | |
|
Zeng L, Holly JM and Perks CM: Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells. Front Endocrinol (Lausanne). 5:612014. View Article : Google Scholar : PubMed/NCBI | |
|
Varghese S, Samuel SM, Varghese E, Kubatka P and Büsselberg D: High glucose represses the anti-proliferative and pro-apoptotic effect of metformin in triple negative breast cancer cells. Biomolecules. 9:162019. View Article : Google Scholar | |
|
Kawakita E, Yang F, Kumagai A, Takagaki Y, Kitada M, Yoshitomi Y, Ikeda T, Nakamura Y, Ishigaki Y, Kanasaki K and Koya D: Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling. Mol Cancer Res. 19:61–73. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Stage TB, Brøsen K and Christensen MM: A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet. 54:811–824. 2015. View Article : Google Scholar | |
|
Bian X, Jiang L, Gan Z, Zhang L, Cai L and Hu X: A glimepiride-metformin multidrug crystal: Synthesis, crystal structure analysis, and physicochemical properties. Molecules. 24:37862019. View Article : Google Scholar | |
|
Scheen AJ: Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 30:359–371. 1996. View Article : Google Scholar | |
|
Palumbo PJ: Metformin: Effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 12:110–119. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Mbara KC, Mato PE, Driver C, Nzuza S, Mkhombo NT, Gcwensa SK, Mcobothi EN and Owira PM: Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. Eur J Pharmacol. 898:1739342021. View Article : Google Scholar | |
|
Notaro ALG and Neto FTL: The use of metformin in women with polycystic ovary syndrome: An updated review. J Assist Reprod Genet. 14:573–579. 2022. View Article : Google Scholar | |
|
Yu Y, Yu L, Cheng N, Liu X, Fang C, Liu S and Zhu L: Exercise alleviates the apolipoprotein A5-toll-like receptor 4 axis impairment in mice with high-fat diet-induced non-alcoholic steatohepatitis. Front Physiol. 12:7833412021. View Article : Google Scholar | |
|
Kalariya NM, Shoeb M, Ansari NH, Srivastava SK and Ramana KV: Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 53:3431–3440. 2012. View Article : Google Scholar | |
|
Agostini F, Masato A, Bubacco L and Bisaglia M: Metformin repurposing for parkinson disease therapy: Opportunities and challenges. Int J Mol Sci. 23:3982021. View Article : Google Scholar | |
|
Ma X, Xiao W, Li H, Pang P, Xue F, Wan L, Pei L and Yan H: Metformin restores hippocampal neurogenesis and learning and memory via regulating gut microbiota in the obese mouse model. Brain Behav Immun. 95:68–83. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JW, Choe JY and Park SH: Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease. Korean J Intern Med. 37:13–26. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Siskind D, Friend N, Russell A, McGrath JJ, Lim C, Patterson S, Flaws D, Stedman T, Moudgil V and Sardinha S: CoMET: A protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. BMJ Open. 8:e0210002018. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor A, Siddiqui MK, Ambery P, Armisen J, Challis BG, Haefliger C, Pearson ER, Doney ASF, Dillon JF and Palmer CNA: Metabolic dysfunction-related liver disease as a risk factor for cancer. BMJ Open Gastroenterol. 9:e0008172022. View Article : Google Scholar | |
|
Sousa AP, Costa R, Alves MG, Soares R, Baylina P and Fernandes R: The impact of metabolic syndrome and type 2 diabetes mellitus on prostate cancer. Front Cell Dev Biol. 10:8434582022. View Article : Google Scholar | |
|
Yang J, Nishihara R, Zhang X, Ogino S and Qian ZR: Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer? J Diabetes Complications. 31:1228–1236. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, Neuhouser ML, Parker DR, Shikany JM, Stefanick ML, et al: A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 18:2046–2053. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X and Ding S: The biological and pharmacological connections between diabetes and various types of cancer. Pathol Res Pract. 227:1536412021. View Article : Google Scholar | |
|
Cook A and Cowan C: Adipose. StemBook. Harvard Stem Cell Institute; Cambridge, MA: 2008 | |
|
Menendez JA, Vazquez-Martin A, Ortega FJ and Fernandez-Real JM: Fatty acid synthase: Association with insulin resistance, type 2 diabetes, and cancer. Clin Chem. 55:425–438. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A and Yakar S: Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes. 116 (Suppl 1):S4–S6. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jayalath VH, Ireland C, Fleshner NE, Hamilton RJ and Jenkins DJ: The relationship between metformin and serum prostate-specific antigen levels. Prostate. 76:1445–1453. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Park JH, Hong JY, Park YS, Kang G, Han K and Park JO: Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study. Metabolism. 123:1548482021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang AMY, Chu KH, Daly BF, Ruiter T, Dou Y, Yang JCC, de Winter TJJ, Chhuor J, Wang S, Flibotte S, et al: Effects of hyperinsulinemia on pancreatic cancer development and the immune microenvironment revealed through single-cell transcriptomics. Cancer Metab. 10:52022. View Article : Google Scholar : PubMed/NCBI | |
|
Lu L, Koo S, McPherson S, Hull MA, Rees CJ and Sharp L: Systematic review and meta-analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Dis. 13:160922022. View Article : Google Scholar | |
|
Nayak S, Rathore V, Bharati J and Sahu KK: Extending the ambit of SGLT2 inhibitors beyond diabetes: A review of clinical and preclinical studies on non-diabetic kidney disease. Expert Rev Clin Pharmacol. 14:1513–1526. 2021. View Article : Google Scholar | |
|
Lam BQ, Srivastava R, Morvant J, Shankar S and Srivastava RK: Association of diabetes mellitus and alcohol abuse with cancer: Molecular mechanisms and clinical significance. Cells. 10:30772021. View Article : Google Scholar : PubMed/NCBI | |
|
Srinivasan M, Arzoun H, Gk LB and Thangaraj SR: A systematic review: Does insulin resistance affect the risk and survival outcome of breast cancer in women? Cureus. 14:e217122022.PubMed/NCBI | |
|
Lemon LS, Orr B, Modugno F, Buckanovich RJ, Coffman L, Edwards RP and Taylor S: Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Gynecol Oncol. 165:60–66. 2022. View Article : Google Scholar | |
|
Choi E, Kikuchi S, Gao H, Brodzik K, Nassour I, Yopp A, Singal AG, Zhu H and Yu H: Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling. Nat Commun. 10:14732019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Zhang B, Zheng W, Kang M, Chen Q, Qin W, Li C, Zhang Y, Shao Y and Wu Y: Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway. Sci Rep. 7:53842017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Huang M, Zhang Q, Chen J, Li J, Han Q, Zhang L, Li J, Liu S, Ma Y, et al: Metformin antagonizes ovarian cancer cells malignancy through MSLN mediated IL-6/STAT3 signaling. Cell Transplant. 30:96368972110278192021. View Article : Google Scholar | |
|
Rho SB, Byun HJ, Kim BR and Lee CH: Knockdown of LKB1 sensitizes endometrial cancer cells via AMPK activation. Biomol Ther. 29:650–657. 2021. View Article : Google Scholar | |
|
Cheng T, Wang C, Lu Q, Cao Y, Yu W, Li W, Liu B, Gao X, Lü J and Pan X: Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer. Free Radic Biol Med. 180:108–120. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Eze C, Belka C and Manapov F: Forging a path for metformin use in inoperable locally advanced non-small cell lung cancer. JAMA Oncol. 7:1341–1342. 2021. View Article : Google Scholar | |
|
Mazurek M, Litak J, Kamieniak P, Kulesza B, Jonak K, Baj J and Grochowski C: Metformin as potential therapy for high-grade glioma. Cancers (Basel). 12:2102020. View Article : Google Scholar | |
|
Zhao A, Xiao H, Zhu Y, Liu S, Zhang S, Yang Z, Du L, Li X, Niu X, Wang C, et al: Omentin-1: A newly discovered warrior against metabolic related diseases. Expert Opin Ther Targets. 10:275–289. 2022. View Article : Google Scholar | |
|
Eibl G and Rozengurt E: Metformin: Review of epidemiology and mechanisms of action in pancreatic cancer. Cancer Metastasis Rev. 40:865–878. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CP, Kuhn J, Shah DP, Schmidt S, Lam YWF, MacCarthy D, Tenner L and Ramirez AG: Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. Cancer Med. 8:3206–3215. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Erkinantti S, Marttila M, Sund R, Arffman M, Urpilainen E, Puistola U, Hautakoski A, Karihtala P, Läärä E and Jukkola A: Association of metformin, other antidiabetic medications, and statins with incidence of colon cancer in patients with type 2 diabetes. Clin Colorectal Cancer. 20:e113–e119. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Febbraro T, Lengyel E and Romero IL: Old drug, new trick: Repurposing metformin for gynecologic cancers? Gynecol Oncol. 135:614–621. 2014. View Article : Google Scholar | |
|
Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D, Xie J, Tao M and Mao Y: Metformin use is associated with better survival of breast cancer patients with diabetes: A meta-analysis. Oncologist. 20:1236–1244. 2015. View Article : Google Scholar | |
|
Wang Q, Ma X, Long J, Du X, Pan B and Mao H: Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 16:135002021. | |
|
Tseng CH: Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer. 50:2831–2837. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Brancher S, Støer NC, Weiderpass E, Damhuis RAM, Johannesen TB, Botteri E and Strand TE: Metformin use and lung cancer survival: A population-based study in Norway. Br J Cancer. 124:1018–1025. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tseng CH: Metformin reduces thyroid cancer risk in taiwanese patients with type 2 diabetes. PLoS One. 9:e1098522014. View Article : Google Scholar : PubMed/NCBI | |
|
Agrawal S, Patel P, Agrawal A, Makhijani N, Markert R and Deidrich W: Metformin use and the risk of esophageal cancer in Barrett esophagus. South Med J. 107:774–779. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Becker C, Jick SS, Meier CR and Bodmer M: Metformin and the risk of endometrial cancer: A case-control analysis. Gynecol Oncol. 129:565–569. 2013. View Article : Google Scholar | |
|
Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A and Szabo E: Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 7:867–885. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Z, Wu L, Zou L, Wang M and Liu X: Metformin induces myeloma cells necrosis and apoptosis and it is considered for therapeutic use. J Chemother. 15:1–11. 2022. View Article : Google Scholar | |
|
Teixeira SF, Guimarães IDS, Madeira KP, Daltoé RD, Silva IV and Rangel LB: Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells. J Bras Pneumol. 39:644–649. 2013.(In English, Portuguese). View Article : Google Scholar | |
|
Lin F, Yan W, Wen T and Wu GY: Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism. Zhonghua Zhong Liu Za Zhi. 35:742–746. 2013.(In Chinese). | |
|
Huang X, Hong X, Wang J, Sun T, Yu T, Yu Y, Fang J and Xiong H: Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis. EBioMedicine. 61:1030372020. View Article : Google Scholar : PubMed/NCBI | |
|
Phoenix KN, Vumbaca F and Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 113:101–111. 2009. View Article : Google Scholar | |
|
Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS and Romanyukha AA: Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 9:188–197. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD and Dennis PA: Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila). 3:1066–1076. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Lachance BB, Mattson MP and Jia X: Glucose metabolic crosstalk and regulation in brain function and diseases. Prog Neurobiol. 204:1020892021. View Article : Google Scholar | |
|
Dai JZ, Wang YJ, Chen CH, Tsai IL, Chao YC and Lin CW: YAP dictates mitochondrial redox homeostasis to facilitate obesity-associated breast cancer progression. Adv Sci. 18:e21036872022. View Article : Google Scholar | |
|
Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PWT and Evans DB: Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg. 144:216–221. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Purcell SA, Oliveira CLP, Mackenzie M, Robson P, Lewis J and Prado CM: Body composition and prostate cancer risk: A systematic review of observational studies. Adv Nutr. 16:1532021. View Article : Google Scholar | |
|
Gong L, Wang Z and Zhang Z: Sestrin2 as a potential target for regulating metabolic-related diseases. Front Endocrinol (Lausanne). 12:7510202021. View Article : Google Scholar : PubMed/NCBI | |
|
Zell JA, McLaren CE, Morgan TR, Lawson MJ, Rezk S, Albers CG, Chen WP, Carmichael JC, Chung J, Richmond E, et al: A phase IIa trial of metformin for colorectal cancer risk reduction among individuals with history of colorectal adenomas and elevated body mass index. Cancer Prev Res (Phila). 13:203–212. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Saini N and Yang X: Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells. Acta Biochim Biophys Sin (Shanghai). 50:133–143. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bang S, Chen Y, Ahima RS and Kim SF: Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action. Mol Endocrinol. 28:1186–1193. 2014. View Article : Google Scholar | |
|
Najafov A, Luu HS, Mookhtiar AK, Mifflin L, Xia HG, Amin PP, Ordureau A, Wang H and Yuan J: RIPK1 promotes energy sensing by the mTORC1 pathway. Mol Cell. 81:370–385. 2021. View Article : Google Scholar | |
|
Kim BH, Han S, Lee H, Park CH, Chung YM, Shin K, Lee HG and Ye SK: Metformin enhances the anti-adipogenic effects of atorvastatin via modulation of STAT3 and TGF-β/Smad3 signaling. Biochem Biophys Res Commun. 456:173–178. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xu S, Lam SK, Cheng PN and Ho JC: Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer. Cancer Sci. 109:3471–3482. 2018. View Article : Google Scholar | |
|
Cameron AR, Logie L, Patel K, Erhardt S, Bacon S, Middleton P, Harthill J, Forteath C, Coats JT, Kerr C, et al: Metformin selectively targets redox control of complex I energy transduction. Redox Biol. 14:187–197. 2018. View Article : Google Scholar | |
|
Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SCJ and Zhang H: Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 5:e10882014. View Article : Google Scholar : PubMed/NCBI | |
|
Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V and Harhaji-Trajkovic L: Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol. 651:41–50. 2011. View Article : Google Scholar | |
|
Athreya AP, Kalari KR, Cairns J, Gaglio AJ, Wills QF, Niu N, Weinshilboum R, Iyer RK and Wang L: Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer. Oncotarget. 8:27199–27215. 2017. View Article : Google Scholar | |
|
Yenmiş G, Beşli N, Saraç EY, Emre FS, Şenol K and Kanıgür G: Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism. Turk J Med Sci. 51:826–834. 2021. View Article : Google Scholar | |
|
Calza G, Nyberg E, Mäkinen M, Soliymani R, Cascone A, Lindholm D, Barborini E, Baumann M, Lalowski M and Eriksson O: Lactate-induced glucose output is unchanged by metformin at a therapeutic concentration-a mass spectrometry imaging study of the perfused rat liver. Front Pharmacol. 9:1412018. View Article : Google Scholar | |
|
Thakur S, Daley B, Gaskins K, Vasko VV, Boufraqech M, Patel D, Sourbier C, Reece J, Cheng SY, Kebebew E, et al: Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo. Clin Cancer Res. 24:4030–4043. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Salani B, Marini C, Rio AD, Ravera S, Massollo M, Orengo AM, Amaro A, Passalacqua M, Maffioli S, Pfeffer U, et al: Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep. 3:20702013. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Y, Xu D, Song H, Qiu B, Tian D, Li Z, Ji Y and Wang J: Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: A systematic review and meta-analysis. BMJ Open. 11:e0483242021. View Article : Google Scholar : PubMed/NCBI | |
|
El-Tanani M, Al Khatib AO, Aladwan SM, Abuelhana A, McCarron PA and Tambuwala MM: Importance of STAT3 signalling in cancer, metastasis and therapeutic interventions. Cell Signal. 92:1102752022. View Article : Google Scholar | |
|
Zahra MH, Afify SM, Hassan G, Nawara HM, Kumon K, Seno A and Seno M: Metformin suppresses self-renewal and stemness of cancer stem cell models derived from pluripotent stem cells. Cell Biochem Funct. 39:896–907. 2021. View Article : Google Scholar | |
|
Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, Uchiyama T, Taniguchi L, Hata Y, Uchiyama S, et al: Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: A multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 17:475–483. 2016. View Article : Google Scholar | |
|
Arrieta O, Zatarain-Barrón ZL, Turcott JG, Barrón F, Yendamuri S, Cardona AF and Rosell R: Association of BMI with benefit of metformin plus epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma: A secondary analysis of a phase 2 randomized clinical trial. JAMA Oncol. 8:477–479. 2022. View Article : Google Scholar | |
|
Pusceddu S, Vernieri C, Di Maio M, Prinzi N, Torchio M, Corti F, Coppa J, Buzzoni R, Bartolomeo MD, Milione M, et al: Impact of diabetes and metformin use on enteropancreatic neuroendocrine tumors: Post hoc analysis of the CLARINET study. Cancers (Basel). 14:692021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, Chen S, Wang G, Lin P, Chen H, et al: Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: Results of a phase II clinical trial. Clin Cancer Res. 26:4921–4932. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB and Bolen S: Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 164:740–751. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wink KC, Belderbos JS, Dieleman EM, Rossi M, Rasch CRN, Damhuis RAM, Houben RMA and Troost EGC: Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol. 118:453–459. 2016. View Article : Google Scholar | |
|
Martin MJ, Hayward R, Viros A and Marais R: Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2:344–355. 2012. View Article : Google Scholar : PubMed/NCBI |
